Manuel Litchman, MD, President, Chief Executive Officer at Mustang Bio discusses his company’s proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies program.
Mustang Bio is focused on the development of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers.
